Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study

Cardiovascular Diseases Clinical Trial

Official title:

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03534908
• Other study ID #: WDRY2017-K009
• Status: Active, not recruiting
• Start date: September 25, 2017
• Est. completion date: June 30, 2021

Study information

• Verified date: October 2019
• Source: Wuhan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world. NAFLD is associated with a lot of comorbidity, such as diabetes, metabolic syndrome, coronary heart disease and chronic kidney diseases. However, the correlation between the NAFLD and cardiovascular disease (CVD) events remains controversial. This study is an observational study based on a big retrospective cohort in china to explore the prevalence of NAFLD in China, the risk factors associated with NAFLD, as well as whether patients with NAFLD are more prone to experience CVDs and CVD events.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5000000
• Est. completion date: June 30, 2021
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• males or females aged 18-75

Exclusion Criteria:

• malignancy except primary liver cancer

• pregnancy or breastfeeding

• liver diseases of other etiology including hepatitis C virus infection ,autoimmune hepatitis,Wilson's disease,hemachromatosis,drug-induced hepatitis,parenteral nutrition

• excessive alcohol consumption

• cases missing crucial data

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Fatty Liver
• Liver Diseases
• NAFLD
• Non-alcoholic Fatty Liver Disease

Locations

Country	Name	City	State
China	Wuhan University	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the prevalence of NAFLD in China		June,2020
Secondary	the risk factors associated with NAFLD		August,2020
Secondary	to indicate the prevalence of CVDs and CVD events in people with and without NAFLD		October,2020